Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 2 of 3
Imugene seeks to activate immune system of cancer patients to identify and eradicate tumours
The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.
Imugene director shows faith in company by exercising options and increasing holding to 13.7 million shares
Imugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene presents HER-Vaxx cancer immunotherapy program at ESMO World Congress on Gastrointestinal Cancer 2021 annual meeting
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene collaborator wins FDA Investigational New Drug approval to initiate CHECKvacc phase one trial
Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug c
Imugene makes key business development appointment
The company believes new chief business officer Dr Monil Shah will make a valuable contribution to advance its immuno-oncology programs.
Imugene believes it has found “the holy grail of cancer therapy”
By combining its cancer-killing virus with CAR T therapy, Imugene hopes to destroy solid tumours.
Imugene MD and chairman demonstrate faith in company by exercising options with total value of $2.524 million
The company has enhanced its portfolio with a novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.
Imugene licenses CD19 Oncolytic virus from City of Hope to turn CAR T therapy against solid tumours
The company has enhanced its portfolio with novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.
Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal
HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Imugene achieves phase-II clinical trial milestone for HER-Vaxx cancer immunotherapy
The important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred.
Imugene presents new data on anti-cancer treatments during prestigious AACR annual meeting
The company presented on the HER-Vaxx cancer immunotherapy program and the CF33 oncolytic virus program during the meeting.
Imugene secures A$0.20 price target from Roth Capital Partners
The company’s cohort review committee has confirmed that its Phase 1 NSCLC trial for checkpoint immunotherapy candidate PD1-Vaxx may proceed to the third and final dose cohort.
Imugene proceeds to third and final highest dose cohort for Phase I clinical trial of PD1-Vaxx, shares up
PD1-Vaxx has been deemed safe with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed at mid-dose (50μg) level and will now escalate to the final highest dose (100μg) cohort.
Imugene secures BUY rating and target price of A$0.20 from Roth Capital Partners
In the near-term, the company expects to release the HER-Vaxx results, progress phase 1 of the PD1-Vaxx clinical trial and start the VAXinia and CHECKvacc clinical programs in the US.
Imguene to present on CF33 and HER-Vaxx immunotherapy programs at American Association for Cancer Research annual meeting
The company will present on the CF33 oncolytic virus program and on the HER-Vaxx cancer immunotherapy program during the prestigious association's annual meeting.
Imugene doses first patient in cohort-2 in phase-I clinical trial of PD1-Vaxx
The company is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene receives approval for phase I clinical trial of new checkpoint immunotherapy candidate PD1-VAX
The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.
Imugene completes recruitment to HER-VAXX Phase 2 gastric cancer trial
The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx
The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.
Imugene boosts cash balance after receiving $4.82 million R&D tax incentive
Receiving the $4,823,466 million in additional funding will further support the company's commercial and clinical milestones.
Imugene Limited phase II trial is highly encouraging: Bell Potter Securities
Bell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy (speculative) recommendation.
Imugene doses first patient in Phase 1 clinical trial of checkpoint immunotherapy candidate PD1-Vaxx for lung cancer
The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.
Imugene up 20% on unveiling positive interim data from ongoing Phase 2 study of HER-Vaxx in advanced gastric cancer
The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study, given the strong signal observed in the data.
Imugene receives FDA IND approval for phase-1 clinical trial of new checkpoint immunotherapy PD1-Vaxx in USA
US FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phase I clinical study in non-small cell lung cancer (NSCLC) patients.
Imugene fully funded to progress four clinical trials in the near-term
During the September quarter, the clinical-stage immuno-oncology company continued to progress clinical programs and remains well-funded to cater for an expected increase in expenditures.
Imugene has a high likelihood of clinical success: Roth Capital Partners
Imugene's oncolytic viruses are designed to infect, replicate in, and kill cancer cells, leaving healthy cells essentially unharmed.
Imugene higher on being granted cancer growth factor immunotherapy combination patent in US
The company recently boosted its balance sheet with a $5.7 million underwriting agreement to support four continuing clinical programs - CF33, PD1, Vaxx and HER-Vaxx as well as provide funding for IP and milestone payments.
Imugene bolsters executive team with appointment of Dr Rita Laeufle as chief medical officer
The company recently entered into an agreement to underwrite outstanding listed options which provides holders with an option to purchase shares in the company at 2.6 cents per share.
Imugene boosts balance sheet with $5.7 million option underwriting agreement
The agreement with Bell Potter further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020.
Imugene gets ethics approval to start Phase 1 clinical trial of immunotherapy candidate for lung cancer in the US
Site activation and patient recruitment will proceed after FDA IND approval scheduled for the fourth quarter of 2020.
Imugene receives third ethics approval to start phase-1 clinical trial of PD1-Vaxx cancer immunotherapy
The ethics approval represents the third independent review of PD1-Vaxx pre-clinical safety and efficacy data.
Imugene guidance from US FDA progresses development pathway for VAXinia product
The FDA provided feedback on the non-clinical development pathway and adaptive phase one clinical development plans for VAXinia, IMU’s lead oncolytic virotherapy for treatment of solid tumours.
Imugene managing director acquires 27 million shares via exercise of options
Last month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.
Imugene given all clear to start phase-1 clinical trial of new cancer immunotherapy PD-1 Vaxx in Australia
The ethics approval represents the second independent review of PD-1 Vaxx pre-clinical safety and efficacy.
Imugene receives ethics approval to start phase 1 clinical trial of new cancer immunotherapy PD1-Vaxx
Ethics approval is confirmation Imugene has completed all the necessary pre-clinical safety and efficacy testing of PD1-Vaxx required to commence human clinical trials.
Imugene research published in prestigious journal titled Frontiers in Immunology
The research has identified mimotope peptides that when incorporated into Imugene’s proprietary immunotherapeutic vaccine delivery platform generate antibodies.
Imugene secures speculative buy recommendation from Bell Potter
HER-Vaxx is Imugene’s lead cancer immunotherapy candidate and is currently treating patients in a phase 2 study in gastric cancer.
Imugene receives independent confirmation of HER-Vaxx safety
The Independent Data Monitoring Committee’s role is to review study data and conduct a formal independent review of key data such as deaths, adverse reactions and laboratory results.
Imugene to virtually present its immuno-oncology clinical plans at Cancer Research 2020
The first-in-human phase 1 study of Vaxinia is in patients with advanced or metastatic melanoma, non-small cell lung, TNBC, bladder, head and neck, gastric, colorectal and renal cell cancers.
Imugene well-placed to advance clinical trials this year
The company is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene non-executive director Lesley Russell demonstrates faith in company with initial on-market purchase
The company is developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene director Charles Walker makes another share purchase
The company is developing a range of treatments to activate the immune system of cancer patients.
Imugene director Charles Walker purchases more shares in the company
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene CEO Leslie Chong demonstrates confidence in immuno-oncology strategy with on-market purchase
The clinical stage immuno-oncology company is developing a range of new treatments seeking to activate the immune system of cancer patients.
Imugene director shows faith in company strategy with on-market share purchase
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene outlines its focus on developing immuno-oncology treatments in half-yearly report
The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
Imugene has CheckVacc preclinical data published in the Journal of American College of Surgeons
The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).
Imugene will trial PD1-Vaxx in patients with non-small cell lung cancer
Pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish as well as processes completed by FDA inspected and qualified contract manufacturing organisations in the US.
Imugene granted HER-Vaxx immunotherapy patent in the US; shares rise 12%
The patent provides method of composition and method of use protection to 2036.
Imugene appoints surgeon-scientist Dr Rebecca Auer to oncolytic virotherapy advisory board
Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.
Imugene’s immunotherapy strategy given stamp of approval in oversubscribed placement
The placement raised A$24.6 million and was well supported by existing investors and new sophisticated and institutional investors.
Imugene director increases stake, capital raising underway
Paul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechnology companies.
Imugene in trading halt with capital raising news pending
The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.
Imugene plans two separate phase I clinical trials for CF33 oncolytic virus
CF33 is a highly potent, chimeric oncolytic poxvirus – a poxvirus refers to a large group of DNA viruses that cause smallpox and similar infectious diseases in vertebrates.
Imugene appoints distinguished physician and scientist to the Scientific Advisory Board
The company’s vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments – this vision is backed by a growing body of clinical evidence and peer-reviewed research.
Imugene shareholders vote yes to completing oncolytic virus acquisition, shares surge
“We are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence of such a promising next-generation oncolytic virus,” says MD and CEO Leslie Chong.
Imugene secures $4.13 million research and development tax refund
Imugene is planning two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a Vaxinia construct of the CF33 oncolytic virus.
Imugene welcomes receipt of US Department of Defense grant for City of Hope cancer researchers
The grant focuses on the area of gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
Imugene plans to begin Phase 1 oncolytic virus technology clinical trials in 2020
Two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a Vaxinia construct of the oncolytic virus.
Imugene appoints world-renowned cancer researcher, physician and surgeon to head-up OV Scientific Advisory Board
A pioneer in the operating room and in the laboratory, Dr Fong, The Sangiacomo Family Chair in Surgical Oncology and chair of The City of Hope Dept of Surgery, is a recognised expert in liver and pancreatic cancer.
Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studies
Inventor Ursula Wiedermann and investigators Tanios Bekaii-Saab and Joshua Tobias presented findings from early study of vaccines for gastric, colon and breast cancers.
Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology
A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.
Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response
HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.
Imugene presents new HER-Vaxx cancer vaccine results
Results were presented at the ASCO annual meeting in Chicago, which attracts over 40,000 cancer specialists.
Imugene appoints venture capital executive to board
The company finished the March quarter with $21 million in the bank.
Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor.
Imugene appoints global pharmaceutical executive to its board
Dr. Lesley Russell brings extensive pharmaceutical experience to the board including a number of cancer therapy collaborations with Teva Pharmaceuticals.
Imugene well-funded to progress clinical milestones
The company is currently fully funded in supporting all clinical research programs.
Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx
The Medical University Vienna and Imugene are working to develop mimotope based cancer vaccines.
Imugene reveals new data on cancer vaccine programs
Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone.
Imugene gets development roadmap for cancer vaccine from FDA meeting
The company had a pre-investigational new drug (IND) meeting with the FDA last month.
Imugene doses milestone first patient for cancer vaccine trial
The first patient was dosed in the Eastern European country of Moldova.
Imugene to make further cancer vaccine research presentations at AACR annual meeting
The AACR annual meeting will be held in Atlanta Georgia, between March 29 and April 3.
Imugene to present cancer vaccine research at AACR annual meeting
The company has multiple B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.
Imugene has cancer vaccine trial data published in prestigious medical journal
Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.
Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Imugene begins manufacture of its innovative cancer vaccine for trials
KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody.
Imugene signs exclusive, world-wide licence for cancer vaccine
Imugene is a clinical stage immuno-oncology company.
Imugene pounces on material acquisition
Imugene is an immuno-oncology company focused on gastric cancer.
Imugene’s shares surge higher following early promise in gastric cancer trial
The company is well funded with a cash balance of circa $12 million as at 31 December 2017.
Imugene targets cash injection for immuno-oncology clinical testing
The halt will remain in place until Thursday 23rd November 2017.
Imugene granted Canadian patent for proprietary cancer vaccine
Immunotherapies are predicted to generate sales of US$36 billion by 2025.
Imugene raises $3M from option plan to advance immunotherapy studies
Imugene is developing an immunotherapy to treat gastric cancer.
Imugene Ltd appoints Leslie Chong to chief executive officer
Imugene Ltd (ASX:IMU) has promoted Leslie Chong to the position of chief executive officer, as the company prepares for the critical milestone of dosing the patients in the gastric cancer Phase 1b/2 clinical trial in Asia.
Imugene gets ready to raise
Imugene Ltd (ASX:IMU) has been granted a trading halt by the ASX, pending details of a capital raising.